Cutler Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-400
| Closed | -$10K | – | 3788 |
|
|
2023
Q2 | $10K | Sell |
400
-11,800
| -97% | -$3.51M | ﹤0.01% | 2233 |
|
|
2023
Q1 | $8K | Sell |
12,200
-48,300
| -80% | -$13.4M | ﹤0.01% | 2433 |
|
|
2022
Q4 | $415K | Buy |
60,500
+800
| +1% | +$226K | 0.04% | 504 |
|
|
2022
Q3 | $432K | Buy |
59,700
+28,100
| +89% | +$5.97M | 0.03% | 599 |
|
|
2022
Q2 | $676K | Buy |
31,600
+13,600
| +76% | +$2.78M | 0.05% | 436 |
|
|
2022
Q1 | $594K | Sell |
18,000
-20,100
| -53% | -$4.37M | 0.03% | 613 |
|
|
2021
Q4 | $270K | Buy |
38,100
+33,400
| +711% | +$8.59M | 0.01% | 1103 |
|
|
2021
Q3 | $138K | Hold |
4,700
| – | – | 0.01% | 1647 |
|
|
2021
Q2 | $100K | Sell |
4,700
-7,000
| -60% | -$2.12M | ﹤0.01% | 1879 |
|
|
2021
Q1 | $76K | Buy |
11,700
+1,700
| +17% | +$458K | ﹤0.01% | 1996 |
|
|
2020
Q4 | $74K | Buy |
10,000
+9,500
| +1,900% | +$2.45M | ﹤0.01% | 1726 |
|
|
2020
Q3 | $7K | Sell |
500
-3,000
| -86% | -$837K | ﹤0.01% | 3220 |
|
|
2020
Q2 | $87K | Sell |
3,500
-1,000
| -22% | -$301K | 0.01% | 1391 |
|
|
2020
Q1 | $83K | Sell |
4,500
-8,200
| -65% | -$2.49M | ﹤0.01% | 1425 |
|
|
2019
Q4 | $85K | Buy |
12,700
+10,600
| +505% | +$2.94M | 0.01% | 1285 |
|
|
2019
Q3 | $46K | Sell |
2,100
-3,500
| -63% | -$815K | ﹤0.01% | 1594 |
|
|
2019
Q2 | $20K | Sell |
5,600
-4,000
| -42% | -$924K | ﹤0.01% | 2196 |
|
|
2019
Q1 | $297K | Sell |
9,600
-21,000
| -69% | -$6.61M | 0.03% | 490 |
|
|
2018
Q4 | $183K | Buy |
30,600
+2,100
| +7% | +$670K | 0.02% | 682 |
|
|
2018
Q3 | $42K | Sell |
28,500
-1,800
| -6% | -$620K | ﹤0.01% | 1716 |
|
|
2018
Q2 | $377K | Sell |
30,300
-400
| -1% | -$112K | 0.03% | 536 |
|
|
2018
Q1 | $686K | Sell |
30,700
-16,700
| -35% | -$5.18M | 0.06% | 316 |
|
|
2017
Q4 | $540K | Sell |
47,400
-54,900
| -54% | -$17.6M | 0.02% | 521 |
|
|
2017
Q3 | $583K | Sell |
102,300
-57,800
| -36% | -$17.1M | 0.02% | 584 |
|
|
2017
Q2 | $4M | Sell |
160,100
-10,000
| -6% | -$2.64M | 0.15% | 117 |
|
|
2017
Q1 | $4.37M | Sell |
170,100
-2,600
| -2% | -$735K | 0.18% | 105 |
|
|
2016
Q4 | $7.83M | Buy |
172,700
+34,400
| +25% | +$10.2M | 0.28% | 45 |
|
|
2016
Q3 | $4.11M | Buy |
138,300
+14,000
| +11% | +$4.15M | 0.18% | 83 |
|
|
2016
Q2 | $9.63M | Buy |
124,300
+104,200
| +518% | +$27.5M | 0.49% | 20 |
|
|
2016
Q1 | $1.29M | Sell |
20,100
-4,900
| -20% | -$1.29M | 0.08% | 204 |
|
|
2015
Q4 | $827K | Buy |
+25,000
| New | +$7.18M | 0.05% | 403 |
|
Other funds holding BIIB
Cutler Group's BIIB Position: Q3 2023 in Review
Cutler Group sold out of Biogen (BIIB) in Q3 2023, closing a stake of 1,106 shares — an estimated $315K sold.
Cutler Group first reported a position in BIIB in Q4 2015 and held it in 29 quarters. The position peaked at $33.3M in Q2 2017. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.
- Cutler Group reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,106 Biogen shares in Q3 2023, an estimated $315K.
- Cutler Group first reported a position in Biogen in Q4 2015 and held it in 29 quarters.
- Cutler Group's Biogen position peaked at $33.3M in Q2 2017.
- 965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.